ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

Phase 3

Conditions: Migraine Prophylaxis

Interventions: Drug: Atogepant

First Posted Date: 2023-02-01

Last Posted Date: 2024-07-12

Lead Sponsor: AbbVie

Target Recruit Count: 650

Registration Number: NCT05707949

Locations: 🇺🇸
My Preferred Research LLC /ID# 250931, Miami, Florida, United States
🇺🇸
Patient Priority Clinical Sites, LLC /ID# 250922, Cincinnati, Ohio, United States
🇺🇸
Access Clinical Trials, Inc. /ID# 250914, Nashville, Tennessee, United States

and more 83 locations

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: ABBV-903
Drug: Placebo for ABBV-903
Drug: Itraconazole

First Posted Date: 2023-01-20

Last Posted Date: 2023-10-30

Lead Sponsor: AbbVie

Target Recruit Count: 104

Registration Number: NCT05691699

Locations: 🇺🇸
Acpru /Id# 251279, Grayslake, Illinois, United States

Expanded Access to Epcoritamab

Conditions: Lymphoma

First Posted Date: 2023-01-20

Last Posted Date: 2023-02-03

Lead Sponsor: AbbVie

Registration Number: NCT05692050

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ABBV-552

First Posted Date: 2023-01-17

Last Posted Date: 2023-04-06

Lead Sponsor: AbbVie

Target Recruit Count: 18

Registration Number: NCT05686980

Locations: 🇺🇸
Anaheim Clinical Trials LLC /ID# 252203, Anaheim, California, United States
🇺🇸
PPD Clinical Research Unit -Las Vegas /ID# 252241, Las Vegas, Nevada, United States

An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World

Recruiting

Conditions: Atopic Dermatitis

First Posted Date: 2023-01-03

Last Posted Date: 2024-12-02

Lead Sponsor: AbbVie

Target Recruit Count: 300

Registration Number: NCT05669794

Locations: 🇫🇷
Ch Saint Quentin /Id# 249270, St Quentin CEDEX, Aisne, France
🇫🇷
CHU Clermont-Ferrand /ID# 248611, Clermont, Auvergne-Rhone-Alpes, France
🇫🇷
Hôpital Européen Marseille /ID# 257643, Marseille, Bouches-du-Rhone, France

and more 56 locations

An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants

Completed

Conditions: Migraine

First Posted Date: 2022-12-16

Last Posted Date: 2024-08-19

Lead Sponsor: AbbVie

Target Recruit Count: 391

Registration Number: NCT05653986

Locations: 🇺🇸
Montefiore/Albert Einstein /ID# 252243, Bronx, New York, United States

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Phase 3

Recruiting

Conditions: Chronic Idiopathic Constipation (CIC)
Functional Constipation (FC)

Interventions: Drug: Placebo for Linaclotide
Drug: Linaclotide

First Posted Date: 2022-12-15

Last Posted Date: 2024-12-18

Lead Sponsor: AbbVie

Target Recruit Count: 116

Registration Number: NCT05652205

Locations: 🇺🇸
G & L Research, LLC /ID# 250658, Foley, Alabama, United States
🇺🇸
Velocity Clinical Research Phoenix /ID# 266280, Phoenix, Arizona, United States
🇺🇸
HealthStar Research of Hot Springs PLLC /ID# 249481, Hot Springs, Arkansas, United States

and more 45 locations

A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections

Phase 4

Completed

Conditions: Facial Lines
Facial Corrections

Interventions: Drug: BOTOX®/VISTABEL®
Device: Juvéderm® VOLBELLA® with Lidocaine
Device: Juvéderm® VOLIFT® with Lidocaine
Device: Juvéderm® VOLUMA® with Lidocaine

First Posted Date: 2022-12-12

Last Posted Date: 2024-10-03

Lead Sponsor: AbbVie

Target Recruit Count: 73

Registration Number: NCT05647551

Locations: 🇦🇺
Dermatology Institute of Victoria /ID# 244786, South Yarra, Victoria, Australia
🇧🇪
Centre de la fontaine /ID# 244763, Gerpinnes, Hainaut, Belgium
🇦🇺
Eastern Plastic Surgery /ID# 244785, Box Hill North, Victoria, Australia

and more 5 locations

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Phase 1

Recruiting

Conditions: Chronic Lymphocytic Leukemia
B Cell Malignancies
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions: Drug: ABBV-525

First Posted Date: 2022-11-16

Last Posted Date: 2024-12-06

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT05618028

Locations: 🇧🇪
UZ Gent /ID# 246462, Gent, Oost-Vlaanderen, Belgium
🇧🇪
Universitair Ziekenhuis Leuven /ID# 246461, Leuven, Vlaams-Brabant, Belgium
🇫🇷
CHRU Lille - Hopital Claude Huriez /ID# 252054, Lille, Nord, France

and more 27 locations

An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis

Recruiting

Conditions: Psoriatic Arthritis

First Posted Date: 2022-11-15

Last Posted Date: 2024-12-18

Lead Sponsor: AbbVie

Target Recruit Count: 450

Registration Number: NCT05616871

Locations: 🇫🇷
Centre Hospitalier Universitaire de Nice - Hôpital Pasteur /ID# 252536, Nice CEDEX 1, Alpes-Maritimes, France
🇫🇷
CHU de Besancon - Jean Minjoz /ID# 252537, Besancon, Doubs, France
🇫🇷
Chic Castres-Mazamet /Id# 259557, Castres CEDEX, Tarn, France

and more 83 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy